http://www.reuters.com/article/pressRelease/idUS154656+08-Sep-200...

http://www.reuters.com/article/pressRelease/idUS154656+08-Sep-2009+BW20090908
Teva will present data on the effect of COPAXONE® on the Multiple Sclerosis
Severity Score (MSSS) from the longest ongoing prospective study of an
immunomodulatory therapy in RRMS. In addition, Teva and Active Biotech (NASDAQ
OMX NORDIC: ACTI) will present data on laquinimod, its investigational oral,
once-daily, immunomodulating compound being developed for the treatment of RRMS.
New data on ATL/TV1102, a second generation antisense inhibitor of CD49d, a
subunit of VLA-4, for the treatment of RRMS patients, will be presented as well.